The merger transforms HSCS into a crypto-mining entity—a fundamental business pivot that introduces significant execution and shareholder-approval risk. Monitor proxy statement for exchange ratio and financial projections. The stock's micro-cap ($9M) and negative historical drift suggest high volatility around the shareholder vote; the non-voting restricted shares and board overhaul add uncertainty.
Price Chart
Executive Summary
HeartSciences filed an 8-K detailing the merger agreement with Fortitude Mining Holdings to transform from an AI-medical-device company into a Zcash mining platform. The filing includes a 425,000-share restricted stock grant to CEO Andrew Simpson as a retention bonus, a $250,000 cash bonus upon closing, and a $50,000 discretionary bonus to CFO Danielle Watson. The board will expand from 5 to 9 directors, with Andrea Childs and Erik Ellingson appointed as CEO and CFO post-closing, pending shareholder approval.
Key Facts
- Merger agreement signed June 23, 2026 with Fortitude Mining Holdings in an all-stock transaction, transforming HeartSciences into a Zcash mining platform.
- CEO Andrew Simpson receives 425,000 restricted shares (non-voting until vested) as a retention bonus, vesting over 1 year after closing.
- $250,000 cash bonus to Simpson payable upon closing, plus $50,000 discretionary bonus to CFO Danielle Watson ($30,000 post-proxy filing, $20,000 at closing).
- Board expands from 5 to 9 directors post-closing; Andrea Childs appointed CEO and Erik Ellingson CFO, replacing Simpson and Watson respectively.
- Plan Amendment No. 4 increases share reserve by 475,000 shares, subject to shareholder approval.
- The merger requires shareholder approval; no financial terms or exchange ratio disclosed.
Financial Impact
425,000 restricted shares issued to CEO as retention; $250,000 cash bonus to CEO; $50,000 cash bonus to CFO. No revenue or earnings figures disclosed.
Risk Factors
- Shareholder approval required; failure to secure votes would terminate the merger.
- No exchange ratio or valuation disclosed; deal terms remain opaque.
- Dilution from 425,000 restricted shares and 475,000 additional plan shares.
- Business model shift from medical devices to crypto mining carries execution, regulatory, and market risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-072722 |
| Document: ea0296127-8k_heartsci.htm | 0001213900-26-072722 |
| Document: ea029612701ex10-1.htm | 0001213900-26-072722 |
| Document: 0001213900-26-072722-index-headers.html | 0001213900-26-072722 |
| Document: 0001213900-26-072722-index.html | 0001213900-26-072722 |
| Document: 0001213900-26-072722.txt | 0001213900-26-072722 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEFA14A | — | awaiting T+1 | — | — |
Oct 26, 2026 today | DEFA14A | — | awaiting T+1 | — | — |
Oct 23, 2026 2d ago | SC 13D/A | $3.41 | awaiting T+1 | — | $3.18 (−6.74%) |
Oct 21, 2026 5d ago | DEFA14A | $3.17 $3.14 | ▼ −0.95% | ▼ −0.42% | $3.18 (+0.32%) |
Oct 19, 2026 7d ago | DEFA14A | $3.13 $3.56 | ▲ +13.74% | ▲ +13.21% | $3.18 (+1.60%) |
Oct 19, 2026 7d ago | DEFA14A | $3.07 $3.13 | ▲ +1.95% | ▲ +1.62% | $3.18 (+3.58%) |
Oct 19, 2026 7d ago | DEFM14A | $3.07 $3.13 | ▼ −1.95% | ▼ −1.62% | $3.18 (−3.58%) |
Oct 15, 2026 11d ago | DEFA14A | $3.02 $3.07 | ▲ +1.66% | ▲ +1.23% | $3.18 (+5.30%) |
Oct 9, 2026 17d ago | 424B5 | $3.30 $3.09 | ▲ +6.36% | ▲ +6.35% | $3.18 (+3.64%) |
Oct 6, 2026 20d ago | DEFA14A | $3.49 $3.04 | ▼ −12.89% | ▼ −12.47% | $3.18 (−8.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers